Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 6/20 | 0.54 |
| ▸ | MME | P08473 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 4/20 | 0.51 |
| ▸ | MMP9 | P14780 | 3/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414333 | 1.00 | CPA1 (0.54) | CPA1MMEMMP2MMP9ADAMTS4 | |
| SCHEMBL28308525 | 1.00 | CPA1 (0.54) | CPA1MMEMMP2MMP9ADAMTS4 | |
| SCHEMBL93589 | 1.00 | CPA1 (0.54) | CPA1MMEMMP2MMP9ADAMTS4 | |
| Hydrochloric Acid SCHEMBL1422098 | 0.98 | CPA1 (0.53) | CPA1MMEMMP2MMP9ADAMTS4 | |
| Water SCHEMBL7180276 | 0.98 | CPA1 (0.53) | CPA1MMEMMP2MMP9ADAMTS4 | |
| Water SCHEMBL28101244 | 0.98 | CPA1 (0.53) | CPA1MMEMMP2MMP9ADAMTS4 | |
| Alanine SCHEMBL28256330 | 0.91 | CTSL (0.47) | CPA1MMEMMP2MMP9L3MBTL1 | |
| SCHEMBL38173 | 0.87 | FOLH1 (0.51) | CPA1MMENAALAD2L3MBTL1 | |
| SCHEMBL38174 | 0.87 | FOLH1 (0.51) | CPA1MMENAALAD2L3MBTL1 | |
| Ethyl Acetate SCHEMBL8046018 | 0.86 | CTSL (0.47) | CPA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2026-05-19 | — | — | US | claimed |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LIMITED (GB) | 2025-02-20 | — | — | US | claimed |
| WO-2024076928-A1 | FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF | ERISYON INC. (US) | 2024-04-11 | — | — | WO | claimed |
| CN-117015290-A | Composite material and preparation method thereof, light-emitting device and preparation method thereof, and display device | TCL科技集团股份有限公司 | 2023-11-07 | — | — | CN | claimed |
| EP-3578566-B1 | BIOCIDAL PEPTIDE AND PREPARATION BASED THEREON | VERTA RES PRODUCTION COMPANY LTD (RU) | 2023-07-19 | — | — | EP | claimed |
| EP-3981781-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-04-13 | — | — | EP | claimed |
| CN-108779150-B | Preparation method of degarelix and intermediate thereof | 费森尤斯卡比依普莎姆责任有限公司 | 2022-03-29 | — | — | CN | claimed |
| EP-3923991-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | Ambrx, Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| EP-3914606-A1 | A CYCLIC PEPTIDE | The University of Queensland (AU) | 2021-12-01 | — | — | EP | claimed |
| EP-3844188-A1 | ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES AND THEIR USES | Ambrx, Inc. (US) | 2021-07-07 | — | — | EP | claimed |
| WO-2000050093-A1 | METHOD OF MEASURING PHYSIOLOGICAL FUNCTION | MALLINCKRODT INC. (US) | 2000-08-31 | — | — | WO | claimed |
| WO-2000033888-A2 | PRODRUG COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COULTER PHARMACEUTICAL, INC. (US) | 2000-06-15 | — | — | WO | claimed |
| EP-0655069-B1 | AMPHIPHILIC COMPOUNDS DERIVED FROM AMINO ACIDS OR PEPTIDES, THEIR METHODS OF SYNTHESIS AND THEIR APPLICATION AS DRUG DELIVERY SYSTEMS | ALLIANCE PHARMA (US) | 1999-11-03 | — | — | EP | claimed |
| WO-1996009813-A9 | DIKETOPIPERAZINE-BASED DELIVERY SYSTEMS | — | 1996-09-26 | — | — | WO | claimed |
| US-5446023-A | Having hydrophilic part derived from polyol, hydrophobic part derived from hydrocarbon linked by amino acid or peptide | ALLIANCE PHARMACEUTICAL CORPORATION (US) | 1995-08-29 | — | — | US | claimed |
| EP-0655069-A1 | AMPHIPHILIC COMPOUNDS DERIVED FROM AMINO ACIDS OR PEPTIDES, THEIR METHODS OF SYNTHESIS AND THEIR APPLICATION AS DRUG DELIVERY SYSTEMS | ALLIANCE PHARMACEUTICAL CORP. (US) | 1995-05-31 | — | — | EP | claimed |
| WO-1995000535-A1 | OPTICALLY PURE CALPAIN INHIBITOR COMPOUNDS | ALKERMES, INCORPORATED (US) | 1995-01-05 | — | — | WO | claimed |
| US-5364851-A | Internal coupling/cyclization to form helical structures | INTERNATIONAL SYNTHECON, LLC (US) | 1994-11-15 | — | — | US | claimed |
| WO-1994003468-A1 | AMPHIPHILIC COMPOUNDS DERIVED FROM AMINO ACIDS OR PEPTIDES, THEIR METHODS OF SYNTHESIS AND THEIR APPLICATION AS DRUG DELIVERY SYSTEMS | S.A. A.T.T.A. APPLICATIONS ET TRANSFERTS DE TECHNOLOGIES AVANCEES (FR) | 1994-02-17 | — | — | WO | claimed |
| WO-1993001206-A1 | CONFORMATIONALLY RESTRICTED BIOLOGICALLY ACTIVE PEPTIDES, METHODS FOR THEIR PRODUCTION AND USES THEREOF | NEW YORK UNIVERSITY (US) | 1993-01-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | PTMS, IL36G, HLA-A | CPA1 1964/4885MME 256/4885MMP2 2377/4885 |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | CD2BP2, CD40, SDC1 | CPA1 1811/4885MME 696/4885MMP2 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.